60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.94 (-0.79% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #524 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, ONCO (Onconetix Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).
Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 48.6 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SXTP currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.00) and Max Pain ($0.99) forces dealer call-delta covering toward $9.05.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
60 Degrees Pharmaceuticals Inc. (SXTP) slipped -0.79% to $0.94, trading at 4% of its 52-week range ($0.59 – $8.62). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Knoxville News Sentinel report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Com
The partnership leverages USM’s established vector biology research expertise and investigator insights into tick-borne disease. Under this agreement, 60 Degrees will underwrite the research and retains an option to
Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report came out today.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #524 by composite RQD confidence (38/100, grade D-) and #971 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SXTP
ACTIVE
60 Degrees Pharmaceuticals Inc. | D- | 38/100 | — | 22.3% | -35.0% | -0.79% | $3.3M | Benchmark Subject |
| ONCO Onconetix Inc. | E | 30/100 | — | 77.6% | -35.0% | -4.27% | $3.3M | /onco-vs-sxtp → |
| GRI GRI Bio Inc. | E | 34/100 | — | — | -35.0% | -2.55% | $3.3M | /gri-vs-sxtp → |
| EOCN Eocene Ltd. | E | 34/100 | — | — | -35.0% | -3.73% | $3.2M | /eocn-vs-sxtp → |
| ERNA Ernexa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -6.63% | $3.2M | /erna-vs-sxtp → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$7.4M | -$6.8M | -$7.0M | $5.4M | $144.0K |
| FY2024 (FY) | 2024-12-31 | $607.6K | -$7.9M | -$5.6M | -$5.8M | $5.8M | $147.1K |
| FY2023 (FY) | 2023-12-31 | $253.6K | -$3.8M | -$4.5M | -$4.5M | — | — |
As of 2026-11-03, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.94 (-0.79% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #524 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, ONCO (Onconetix Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M) and GRI (GRI Bio Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.3M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).
Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SXTP last traded at $0.94 (-0.79% on volume of 73,529 shares), positioning the stock -6.00% below its 50-day simple moving average ($1.00) and -46.59% below its 200-day simple moving average ($1.76). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.4% percentile with a 14-day RSI of 48.6 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).
Why SXTP Stock slipped -0.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, SXTP scores 38 / 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
For a prospective investor, the rating points to a company with negative operating economics and cash burn, where the principal support is a low debt load rather than earnings or cash generation. Upside drivers in the source data are limited to catalysts described in the news wire; valuation tradeoffs are severe, since the company is reported at a $3.3M market capitalization with a 52-week range of $0.59 - $8.62. The rating is analytical, not a recommendation.
60 Degrees Pharmaceuticals Inc. (SXTP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. Reported revenue was $1.0M for FY 2025, per the SEC financials. Not available in source data for further detail on how the company earns revenue.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $1.0M | $-7.8M | $-7.4M | N/A | $-7.0M | $1.5M | $0.1M |
| FY 2024 | $0.6M | $-9.7M | $-7.9M | N/A | $-5.8M | $1.7M | $0.1M |
| FY 2023 | $0.3M | $-5.2M | $-3.8M | N/A | $-4.5M | N/A | N/A |
Per the SEC financials, revenue rose across the three reported periods while operating and net losses persisted in each year. Per the market data, the gross margin is 22.3%, the operating margin is -60%, the net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with a Debt/Equity of 0.04. Reported debt is small relative to cash, though cash declined from $1.7M to $1.5M across FY 2024 to FY 2025 while free cash flow remained negative.
Per the recent news and catalysts feed (all items tagged to SXTP):
Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for 60 Degrees Pharmaceuticals Inc. (SXTP) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Knoxville News Sentinel report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
TradingView report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.
Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Com
Welcome to the SXTP (60 Degrees Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on SXTP, but look at what you are paying: current EV/EBITDA multiples with 22.3% gross margins. Unless 60 Degrees Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on SXTP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.95 (52-wk range $0.59 - $8.62), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).